Insider · CIK 0001563786
Clark Golestani
Files at ZPTA (Zapata Quantum, Inc.). First filing -, latest -.
In brief
Clark Golestani files SEC Form 4 as director at ZPTA (Zapata Quantum, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Clark Golestani has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 9, 2025 | ZPTA Zapata Quantum, Inc. | AGrant or award Stock Options (Right to Buy)derivative | +1,000,000 | $0.00 | $0 | 1,000,000 | Oct 10, 2025 |
| Jun 13, 2025 | ZPTA Zapata Quantum, Inc. | AGrant or award Common Stock | +32,500,000 | $0.00 | $0 | 32,626,288 | Jun 16, 2025 |
| Jun 12, 2025 | ZPTA Zapata Quantum, Inc. | POpen-market purchase Convertible Promissory Notederivative | - | $100,000.00 | - | - | Jun 16, 2025 |
| Jun 12, 2025 | ZPTA Zapata Quantum, Inc. | POpen-market purchase Warrantderivative | +1,250,000 | - | - | 1,250,000 | Jun 16, 2025 |
Questions about Clark Golestani
Answered from the filings on this page, as of the latest one.
Is Clark Golestani buying or selling?
Clark Golestani has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Clark Golestani's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Clark Golestani has 0.
Where does Clark Golestani file Form 4?
Clark Golestani has filed Form 4 at ZPTA (Zapata Quantum, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.